Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray

Laura M. Walker1 and Dennis R. Burton2–4

Abstract | Antibodies have been used for more than 100 years in the therapy of infectious diseases, but a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies (sometimes referred to as ‘super-antibodies’) offers new opportunities for intervention. The isolation of these antibodies, most of which are rarely induced in human infections, has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation. Engineering the antibodies to improve half-life and effector functions has further augmented their in vivo activity in some cases. Super-antibodies offer promise for the prophylaxis and therapy of infections with a range of viruses, including those that are highly antigenically variable and those that are newly emerging or that have pandemic potential. The next few years will be decisive in the realization of the promise of super-antibodies.

The use of antibodies to ameliorate the adverse clinical effects of microbial infection can be traced back to the late 19th century and the work of von Behring and Kitasato on the serum therapy of diphtheria and tetanus (reviewed in REFS 1,2). In these settings, the antibodies act to neutralize bacterial toxins. Therapies followed in which serum antibodies were targeted directly against bacterial and then viral pathogens. For viral pathogens, enriched polyclonal IgG molecules from immunized animals were shown to be effective in prophylaxis, and even prophylaxis after exposure, for a number of viruses, including hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, measles virus, rabies virus, respiratory syncytial virus (RSV), smallpox virus and varicella zoster virus. In general, the effectiveness of antibody preparations declined with the duration of infection such that they were often regarded as poor therapeutic options. Of course, the major antiviral strategy of the 20th century was vaccination.

Over the latter part of the 20th and early part of the 21st century, there have been major developments in our understanding of antibodies and our ability to manipulate them. The advent of hybridoma technology in 1976 provided a reliable source of mouse monoclonal antibodies (mAbs), the first impact of which was not on antibody therapy but on the characterization of cells through the definition of cell surface markers. Broad implementation of mAbs in therapy had to wait until the development of humanized mouse antibodies and then the generation of fully human antibodies by various techniques described below. Such antibodies have been largely applied in the fields of oncology and autoimmunity. Only a single antiviral mAb, the RSV-specific antibody palivizumab, is in widespread clinical use. The reasons for this have been discussed elsewhere3–4, although perhaps the most important reasons are the fairly high cost of the production of mAbs, the difficulties of administration and a belief that antibodies are largely effective only in a prophylactic setting, which can be achieved for many viruses by vaccination.

However, as we discuss here, an increasing number of antiviral antibodies with quite remarkable properties in terms of potency and/or cross reactivity with other viruses or strains of the same virus are being isolated. These so-called super-antibodies are changing our understanding of what we can hope to achieve with antibodies against microbial infection in the clinic. Increased potency can greatly reduce the unit costs of treatment, make alternative routes of administration feasible and extend the effective half-life of the antibody. Increased cross reactivity can allow us to consider targeting multiple viruses with single antibodies. Antibody engineering can impact both potency and cross reactivity and can greatly extend the half-life of super-antibodies.

In this Review, we discuss how new approaches have fuelled the identification of super-antibodies, where and how such antibodies may be best applied and future directions for the field.
Super-antibody discovery

Many acute viral infections induce robust neutralizing antibody responses in the large majority of individuals. In general, these viruses show little evidence for evasion of antibody responses, and we have referred to them as ‘evasion light’ viruses. Typically, they either display limited antigenic variability in their surface protein (or proteins) or show considerable variability but nevertheless express immunodominant, conserved epitopes. Examples of viruses in this category include measles virus, poliovirus, chikungunya virus and RSV. The life cycle of these viruses presumably does not dictate immune evasion. For these types of viruses, the isolation of super-antibodies from immune donors has been achieved in a fairly straightforward manner. However, some viruses have evolved mechanisms to evade effective neutralizing antibody responses (termed ‘evasion strong’ viruses) and induce such responses at much lower levels. Effective responses in the context of infection with highly antigenically variable viruses refers not only to their neutralization potency but also to their effectiveness against diverse circulating global isolates, often referred to as breadth. For these viruses — including HIV, influenza virus, Ebola virus and Lassa virus — only a proportion of infected individuals, sometimes quite small, will generate broad and potent neutralizing antibody responses. Furthermore, within these individuals, potent broadly neutralizing antibody (bnAb) specificities generally constitute only a small fraction of the antigen-specific memory B cell pool.

For example, only a small percentage of HIV-infected individuals develop broad and potent serum responses over time, and B cell cloning efforts have demonstrated that bnAbs generally comprise <1% of the HIV envelope (Env)-specific memory B cell repertoire. Although there are probably multiple factors that contribute to the low abundance of bnAbs within these individuals, the intrinsic nature of the viral Env protein likely has a key role. The HIV Env protein has evolved a multitude of mechanisms to evade bnAb responses, including decoy forms of Env, enormous antigenic variability, an evolving glycan shield, immunodominant and variable epitopes and poorly accessible conserved epitopes. Furthermore, most HIV-specific bnAbs incorporate unusual features for epitope recognition, such as uncommonly long (or short) complementarity determining region 3 (CDR3) loops, insertions and deletions, tyrosine sulfation and extensive somatic hypermutation, that likely also contribute to the rarity and delayed development of bnAbs during natural infection.

In the case of influenza virus infection, the vast majority of neutralizing antibodies elicited by infection or vaccination bind to variable epitopes within the haemagglutinin (HA) globular head of the viral particles and display strain-specific neutralizing activity. Influenza virus-specific bnAbs typically target the conserved HA stem, but this region has variable immunogenicity. The relatively low frequency of bnAbs against the HA stem is perhaps due to the typically tight packing of HA trimers on the virus surface, which may limit antibody accessibility to this region. For Ebola and Lassa viruses, extensive glycosylation on the surfaceEnv proteins results in masking of conserved neutralizing epitopes. In cases where super-antibodies are present at low frequency within immune repertoires, large-scale donor screening and high-throughput B cell isolation platforms have proved to be critical for the discovery of super-antibodies. Over the past several years, technological advances in these two areas have led to the identification of large numbers of super-antibodies, mostly from infected individuals, against a plethora of viral pathogens.

Large-scale donor screening

In the case of HIV, which has served as a prototype virus for many studies in this field, systematic selection of donors with broadly neutralizing serum responses has proved to be critical for the identification of super-antibodies. Before 2009, the HIV field had been operating with a handful of bnAbs, all of which were limited either in breadth or in potency. A number of factors complicated the identification of bnAbs, including the inefficiency of traditional approaches to mAb discovery, the small fraction of B cells that secrete bnAbs and the limited availability of samples from donors who had developed broad and potent neutralizing serum responses. Beginning in 2005, the problem of limited samples was addressed by establishing donor screening programmes to identify HIV-infected individuals with broadly neutralizing serum responses to serve as source material for the generation of bnAbs. In one of the largest studies, ~1,800 HIV-infected individuals from Australia, Rwanda, Uganda, the United Kingdom and Zambia were screened for broadly neutralizing sera using a reduced pseudo-virus panel representative of global circulating HIV isolates. A subset of individuals, termed ‘elite neutralizers’, was identified that exhibited exceptionally broad and potent neutralizing serum responses and was therefore prioritized for bnAb isolation.

Over the past 8 years, mining of these and similar samples has led to the identification of dozens of remarkably broad and potent HIV super-antibodies. Careful selection of donors with desirable serum profiles has also enabled the isolation of rare super-antibodies to influenza virus, RSV, human metapneumovirus (HMPV), rabies virus and Zika virus. For example, the pan-influenza A virus-neutralizing mAb FI6 and the RSV and HMPV cross-neutralizing mAb MPE8 were isolated from donors who were selected on the basis of their strong heterotypic serum responses. Similarly, two pan-lyssavirus-neutralizing mAbs, called RV2C0 and RVC58, were isolated from the memory B cells of four donors who exhibited potent serum-neutralizing activity against multiple lyssavirus species.

High-throughput human B cell isolation technologies

Human antiviral neutralizing mAbs have been isolated using various different technologies, including combinatorial display libraries, human immunoglobulin transgenic mice and single B cell isolation methods. Although all of these technologies have proved valuable for mAb generation, the recent burst in super-antibody discovery.
Figure 1 | Technologies for monoclonal antibody generation. a | Combinatorial display libraries. Human antibody heavy-chain and light-chain genes are amplified by reverse transcription (RT)-PCR, and antibody fragments are displayed on the surface of a particle or cell in which the antibody genes are found (such as phage, yeast or mammalian cells). Successive rounds of enrichment are performed to select for clones that bind to the target antigen. Genes encoding antibodies of interest are cloned into human IgG expression vectors to produce monoclonal antibodies (mAbs). b | Human immunoglobulin transgenic mice are generated by introducing human immunoglobulin loci into the mouse genome. Upon immunization, the transgenic mice produce fully human antigen-specific antibodies. The B cells harvested from the immunized mice are fused with myeloma cells to generate antibody-secreting hybridomas, which are then screened for binding or functional activity. c | Single B cell cloning. Antigen-specific memory B cells or plasmablasts are single-cell sorted by flow cytometry, and cognate heavy-chain (VH) and light-chain (VL) variable genes are amplified by single-cell PCR. The antibody variable genes are cloned into human IgG expression vectors to produce mAbs. d | Memory B cell immortalization. Memory B cells are immortalized by Epstein–Barr virus (EBV), and B cell culture supernatants are screened for binding or functional activity. Positive cultures are subcloned by limiting dilution. e | Memory B cell culture. Single B cells are activated and cultured, and B cell supernatants are screened for binding or functional activity. Antibody variable genes are amplified from clones of interest by PCR and cloned into human IgG expression vectors to produce mAbs. FACS, fluorescence-activated cell sorting.
discovery has primarily been driven by advances in single B cell-based methods. There are several possible reasons for this, including inefficiencies in combinatorial library generation and interrogation (leading to the loss of rare clones), altered binding characteristics of antibody fragments produced in heterologous expression systems (for example, *Escherichia coli* or yeast), constraints on the generation of suitable recombinant antigens for immunization or library selections, the loss of native heavy-chain and light-chain pairing during immune library generation and inherent differences between the adaptive immune systems of humanized mice and humans.

Several technological breakthroughs in the B cell cloning arena have been most critical in fuelling super-antibody identification. One of these advances came in 2009, when direct functional screening of thousands of B cell clones from an HIV elite neutralizer led to the isolation of two super-antibodies, PG9 and PG16, that were approximately an order of magnitude more potent than first-generation bnAbs.27 Notably, PG9 and PG16 bind poorly to recombinant Env proteins and thus would not have been identified without direct functional screening of B cell supernatants. To date, many dozens of HIV-specific bnAbs targeting a diverse range of epitopes have been identified using functional screening approaches.46–48. Highly potent super-antibodies to RSV, HMPV, Lassa virus and human cytomegalovirus (HCMV) have also been discovered using high-throughput functional screening technologies.43,49–50 (TABLE 1).

Similar to PG9 and PG16, these super-antibodies were isolated by screening B cell supernatants on the basis of their capacity to neutralize infection in vitro and were subsequently found to react poorly with currently available recombinant Env proteins. In the case of RSV, this approach led to the isolation of the highly potent mAb D25, which binds to an epitope that is exclusively expressed on the prefusion conformation of RSV fusion glycoproteins (F proteins).49,51. An engineered variant of mAb D25 (MEDI8897), which exhibits 50–100 times greater neutralization potency than palivizumab, is now being tested in clinical trials for the prevention of RSV-associated disease in high-risk infants. A second RSV prefusion F-protein-specific super-antibody, which cross-neutralizes several different paramyxoviruses, including HMPV, was also isolated by screening B cell supernatants for neutralizing activity52 (TABLE 1).

In the case of HCMV, direct functional screening enabled the isolation of highly potent super-antibodies specific for conformational epitopes within the gH–gL–gO pentamer complex, which was not previously known to be a target for neutralizing antibodies.41. Direct functional screening approaches have also led to the discovery of potent super-antibodies to Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola virus, influenza virus, chikungunya virus, rabies virus and the poxvirus family.9,42,43,52–56. Notably, in the case of MERS-CoV, only 1 B cell culture out of 4,600 screened showed neutralizing activity.53. Similarly, the pan-influenza A virus-neutralizing mAb F16 was isolated by testing 104,000 plasma cells from eight immune donors.42. Finally, only 2 of 500 mAbs that were selected on the basis of their ability to neutralize rabies virus showed cross-neutralizing activity against multiple lyssavirus species.43. These examples clearly illustrate that exhaustive interrogation of immune repertoires is often required for the identification of rare cross-neutralizing super-antibodies.

A second breakthrough in the HIV antibody field followed the development of technology for antigen-specific single B cell sorting57–59. This approach, coupled with the use of rationally designed Env probes, allowed for the discovery of two new potent HIV-specific bnAbs that target the conserved CD4 binding site60,61 (TABLE 1). Following this discovery, several other potent bnAbs against the CD4 binding site were isolated through the use of similar approaches.60,62,63. Recently, advances in the generation of recombinant native-like HIV Env trimers have enabled the identification of exceptionally potent ‘PG9-class’ bnAbs.64.

Many HIV super-antibodies have now been generated with the use of single B cell sorting technologies.64,60,62,63,66. The use of fluorescently labelled probes to sort antigen-specific memory B cells has also enabled the discovery of highly potent super-antibodies to Ebola virus, RSV, human papilloma virus (HPV), Zika virus and influenza virus63,64,65,66. In the case of Ebola virus, a large-scale single B cell cloning effort led to the isolation of several hundred mAbs specific for Ebola virus envelope glycoprotein (GP), two of which showed potent pan-Ebola virus-neutralizing activity and protective efficacy.64,65. A similar effort in the RSV field allowed for the isolation of several prefusion F-protein-specific mAbs that show over 100 times more potent neutralizing activity than palivizumab.61. In addition, multiple groups have used clever dual-antigen labelling strategies to identify potent bnAbs to HIV, influenza virus, Ebola virus and HPV63,64,65,66,67,68. The structures of several super-antibodies bound to their viral targets are shown in FIGURE 2. Finally, a recent report showed that bnAbs to HIV can be readily elicited in cows through the use of a single Env trimer immunogen and that this induction depends on the long heavy-chain CDR3 loops of the bovine immunoglobulin repertoire.69. It is possible that this repertoire may provide advantages in generating super-antibodies against other pathogens.

Vaccination or infection-induced antibody-secreting cell (ASC) responses have also proved to be a rich source of antigen-specific antibodies. Following early studies that showed that a transient but large population of ASCs appears in peripheral blood 5–7 days after tetanus toxoid booster vaccination70, it was shown that influenza virus vaccination produced a similar ASC response and that the large majority of mAbs cloned from these cells bound with high affinity to influenza virus, providing a proof of concept that the ASC response could be exploited to rapidly generate antigen-specific antibodies against any immunizing antigen70. To date, plasmablast cloning has led to the isolation of mAbs against many different viruses, including dengue virus, Zika virus, HIV, influenza virus, vaccinia virus and rotavirus.72–76.
One of the advantages of the plasmablast approach is that antigen baiting is not required for B cell sorting, thereby allowing for the isolation of antibodies that target epitopes that are poorly presented on recombinant antigens. For example, in the case of dengue virus, potent bnAbs targeting E-dimer-dependent epitopes were isolated using this approach. However, it is important to emphasize that the ability to isolate super-antibodies using this method will depend on several factors. First, during a primary infection, the ASC population will be mainly composed of activated, low-affinity naive B cells (rather than affinity-matured memory B cells), making the possibility of identifying super-antibodies extremely unlikely. Second, in the context of a booster vaccination or secondary infection with an antigenically similar virus, most of the plasmablast response will be directed against immunodominant epitopes, which in many cases are not targeted by effective neutralizing antibodies. In such cases, exhaustive cloning, production and characterization of the plasmablast-derived mAbs would likely be required to identify rare super-antibodies. By contrast, secondary infection with an antigenically related but sufficiently divergent virus can drive the preferential expansion of B cells that target highly conserved epitopes, as exemplified by the unusually high frequency of bnAbs induced in donors who were infected with the novel H1N1 influenza virus in 2009 (REFS 29, 75). In principle, one could use this type of approach for the generation of super-antibodies in humanized mice or other animal models by using suitably designed immunogens and immunization regimens.

Table 1 | Antiviral super-antibodies

| Virus                  | Prototypic super-antibody | Similar antibodies* | Antigenic region | Antibody isolation technology |
|------------------------|---------------------------|---------------------|-----------------|-----------------------------|
| HIV                    | PG9 and PGT145            | PG16, PGT141-144, CH01-04, PGDM1400-1412 and CAP256-VRC26.01-12 | V2 apex | Human B cell isolation |
| VRC01                  | VRC02, VRC03, 8ANC131, 8ANC37, 8ANC134, NIH45-46, 3BNC60, BNC62, 3BNC117, 12A12, 12A21, 12A30, VRC-PG04, VRC-CH51, VRC27, VRC07-523 and N6 | CD4 binding site | Human B cell isolation |
| PGT121, PGT128 and PGT135 | PGT122, PGT123, PGT125-PGT127, PGT130, PGT131, PGT136, PGT137, 10-1074 and BG18 | V3 glycan | Human B cell isolation |
| PGT151, 35O22 and 8ANC195 | PGT152-158, ACS202 and N123-VRC34.01 | gp120–gp41 interface | Human B cell isolation |
| 10E8                   | None identified            |                      |                 | Human B cell isolation |
| Influenza virus        | C05                        | F045-092 and 6411-9 | HA head | Human B cell isolation, phage display |
| Fi6                    | MEDI8852, CR9114, 39,29, 81,39, CT149, 56.a.09, 31.b.09, 16.a.26 and 31.a.83 | HA stem | Human B cell isolation |
| RSV and HMPV           | MPE8                       | ADI-14448 and 25P13 | Site III | Human B cell isolation |
| RSV                    | D25                        | AM22, 5C4 and ADI-15618 | Site ø | Human B cell isolation |
| HCMV                   | 9i6 and 8i21               | 1F11, 2F4 and 6G4 | Pentameric complex | Human B cell isolation |
| Rabies virus           | RVC58                      | None identified     | Site III | Human B cell isolation |
| RVC20                  | None identified            |                      | Site I | Human B cell isolation |
| Dengue virus and Zika virus | A11 and C8             | C10, B2, B7 and C4 | E-dimer interface | Human B cell isolation |
| Z004                   | Z028, Z001, Z006, Z010, Z031, Z035, Z038, Z014, ZKA-190, ADI-24192, ADI-24232, ADI-24227 and ADI-24238 | DIII lateral ridge | Human B cell isolation |
| Ebola virus            | ADI-15878                  | 6D6, ADI-15742, CA45 and FVM09 | Fusion loop | Human or macaque B cell isolation |
| MERS-CoV               | LCA60, REGN3051 and REGN3048 | None identified     | Receptor-binding domain | Human B cell isolation, humanized mice |
| Lassa virus            | 8.9F                       | None identified     | Quaternary GPC-C epitope | Human B cell isolation |
| 37.2D                  | 25.6A                      | None identified     | Quaternary GPC-B epitope | Human B cell isolation |
| 25.10C and 12.1F       | None identified            |                      | Quaternary GPC-A epitope | Human B cell isolation |

*This list of antibodies is not exhaustive and is caveated by the fact that different neutralization assays can give different results. gp120, envelope glycoprotein gp120; gp41, glycoprotein 41; GPC, glycoprotein complex; HA, haemagglutinin; HCMV, human cytomegalovirus; HMPV, human metapneumovirus; MERS-CoV, Middle East respiratory syndrome coronavirus; MPER, membrane-proximal external region; RSV, respiratory syncytial virus.
Rapid response platforms for emerging viruses

Over the past two decades, humanity has faced a newly emerging, or re-emerging, viral threat almost every year, including severe acute respiratory syndrome coronavirus (SARS), West Nile virus, pandemic influenza virus, Ebola virus, MERS-CoV and Zika virus. Because of their comparatively fast path to approval and generally favourable safety profiles, mAb therapies represent a promising alternative to vaccines and small-molecule drugs for the treatment and prevention of emerging viral threats. Recently, several laboratories have demonstrated the feasibility of identifying, characterizing and scaling-up production of highly potent mAbs in remarkably short time frames.

In response to the 2014–2015 MERS-CoV outbreak, two different groups illustrated the power of their mAb discovery platforms by isolating highly potent MERS-specific mAbs, producing the mAbs in gram quantities, and screening the lead mAbs in animal models at an unprecedented speed. In one of these studies, a single highly potent MERS-CoV-neutralizing mAb was identified from the memory B cells of a convalescent donor through the use of high-throughput functional screening approach. This mAb, called LCA60, showed protection both before and after exposure in a mouse model of MERS-CoV infection. Importantly, this process took the authors only 4 months from the initial B cell screening to the development of a stable cell line that produces the neutralizing mAb at 5 g l\textsuperscript{-1}. In the second study, human immunoglobulin transgenic mice were immunized with the MERS-CoV spike protein and then used to generate a panel of potent MERS-CoV-specific neutralizing mAbs within several weeks. The authors also quickly generated a humanized mouse model of MERS-CoV infection, which was used to demonstrate the therapeutic efficacy of their mAbs.

In a third study, vaccination of transchromosomal cows engineered to produce fully human IgG molecules with MERS-CoV was shown to yield high serum titres of MERS-CoV-specific neutralizing antibodies. Importantly, administration of the purified polyclonal transchromosomal bovine human IgG to mice either 12 hours before or 24 and 48 hours after MERS-CoV infection resulted in a significant reduction in viral lung titres. Transchromosomal bovines have also been used to rapidly generate polyclonal neutralizing antibodies to Hanta virus, Venezuelan equine encephalitis virus and Ebola virus, demonstrating the feasibility of using this platform to rapidly generate therapeutics to combat emerging viral threats. The antibodies arising from transchromosomal cows are polyclonal to date, but there is potential for mAb isolation.

Between 2015 and 2016, several groups responded to the 2014–2015 Ebola virus outbreak by swiftly generating highly potent Ebola virus GP-specific neutralizing mAbs from the memory B cells of convalescent donors. Many of these mAbs showed potent therapeutic efficacy against either Ebola or Bundibugyo virus after exposure in animal models and a subset showed protective efficacy against multiple Ebola virus strains. Notably, one of these neutralizing mAbs, called ZIKV-117, showed protection against Zika virus after exposure in both pregnant and nonpregnant mice. In certain cases, the availability of super-antibodies that target highly conserved epitopes may shorten timelines further by bypassing the need for mAb discovery. For example, it was recently shown that a subset of dengue-virus-specific mAbs potently cross-neutralizes Zika virus. These bnAbs — perhaps carrying Fc mutations that ablate Fc receptor binding to avoid the potential for antibody-dependent enhancement — could immediately be used for prophylaxis for pregnant women living in Zika-virus-endemic regions. Notably, cocktails of super-antibodies targeting different epitopes, or bispecific or trispecific super-antibody constructs, will likely be required to prevent neutralization escape.
free virus particles and activities against infected cells. Neutralization, measured in vitro as the ability of an antibody to prevent viral entry into target cells without a requirement for involvement of any other agents, is an activity against free virions that has been most correlated with protection in vivo. Activities against infected cells generally depend on Fc effector functions and involve host effector cells. They include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity and antibody-dependent cellular phagocytosis (ADCP). It is presumed that these activities are likely to be important in antibody-based therapy. Because neutralization frequently correlates with the ability to bind to native structures on the virion surface, it can give some indication of the ability of antibodies to mediate effector activities such as ADCC and ADCP. The potency of super-antibodies is then often estimated from neutralization measurements, although ultimately it is of course in vivo activity that is crucial.

**Prophylaxis.** Vaccination is the most effective and low-cost method of preventing viral disease. However, the development of effective vaccines against many important viral pathogens — including HIV, RSV, hepatitis C virus, dengue virus and HCMV — has been met with limited success. Furthermore, vaccine development is a long complex process, often lasting 10–15 years, making immunization an impractical means of protecting individuals from newly emerging viral threats unless pan-virus family vaccines can be developed. For example, if antibodies can be identified that potently neutralize existing strains of Ebola virus, or even Ebola and Marburg filoviruses, then one could anticipate that a vaccine templated from the antibodies would also be effective against emerging strains of Ebola virus. However, at the current time, passive antibody prophylaxis represents a promising alternative to vaccination for a number of viral infections.

Currently, three purified polyclonal hyperimmune globulins derived from human donors immune to hepatitis B virus, HCMV or varicella zoster virus are on the market for the prevention of serious diseases associated with these viruses. A rabies-virus-specific immune globulin, combined with vaccination, is also available for prophylaxis after exposure. In 1998, palivizumab — a humanized mAb that targets the RSV F protein — became the first antiviral mAb approved by the US Food and Drug Administration. Palivizumab soon replaced the RSV hyperimmune globulin (RespiGam) for the prevention of severe RSV-associated disease in high-risk infants. However, although palivizumab is more specific and 50–100 times more potent than RespiGam, the cost associated with the required dosing makes its use impractical for all infants93. A second-generation RSV-specific mAb, which shows up to 50 times greater neutralization potency than palivizumab and contains substitutions in the Fc domain that extend its serum half-life, is currently in phase II clinical trials for the prevention of severe RSV-associated disease in all infants95 (TABLE 2).

Although palivizumab is the only commercially available mAb for the prevention of a viral disease, there are multiple antiviral mAbs in preclinical and clinical development that have shown efficacy prior to exposure in animal models. For example, the potent MERS-CoV-specific mAbs described above were shown to prophylactically protect humanized mice against MERS-associated disease. Similarly, mAbs to chikungunya virus, influenza virus, HIV and Ebola virus have shown potent prophylactic efficacy in animal models9,38,96–102. Recently, a broadly neutralizing anti-Zika virus mAb (ZIKV-117) was shown to protect against maternal–fetal transmission in a mouse model of Zika virus infection95. If this observation translates to humans, prophylaxis with ZIKV-117 or similar neutralizing mAbs may be a promising means of protecting at-risk pregnant women against Zika virus infection and fetal transmission.

In the case of HIV, multiple studies have shown that passively administered neutralizing mAbs provide protection against intravenous, vaginal, rectal and oral challenge in nonhuman primate and mouse models96–102,103–106. A large ongoing study (the Antibody-Mediated Prevention (AMP) study) will assess the ability of the VRC01 mAb specific for the CD4 binding site to decrease the risk of HIV acquisition in humans. Although animal studies have provided proof of principle that a vaccine capable of inducing sufficient titres of bnAbs could prevent the establishment of HIV infection in humans, and the AMP study will investigate this directly, the design of immunogens that efficiently elicit these rare antibodies remains a formidable challenge.

To bypass the challenges associated with active vaccination against HIV, a number of groups have proposed alternative strategies on the basis of vector-mediated antibody gene transfer to express bnAbs in vivo107. Unlike traditional passive immunization, which would require long-term repeated treatment with bnAbs, vectored immunoprophylaxis involves only a single injection and enables continuous and sustained delivery of antibodies. In 2009, pioneering work demonstrated that vector-mediated delivery of antibody-like molecules can provide vaccine-like protection against simian immunodeficiency virus (SIV) challenge in nonhuman primate models108. Subsequent studies have shown that vectored immunoprophylaxis is also compatible with full-length IgG molecules and CD4-like molecules109–111. If the preclinical results in mice and macaques translate to humans, vectored antibody gene delivery strategies could provide an alternative form of prophylaxis against HIV and other challenging vaccine targets, such as hepatitis C virus, pandemic influenza virus and malaria. Recently, non-viral vector nucleic acid delivery technologies have also been developed to obviate the potential safety issues associated with viral vector-mediated delivery, such as long-term persistence and potential viral DNA integration into the host genome112–117. In a recent study, it was shown that the administration of lipid-encapsulated nucleoside-modified mRNAs encoding the heavy-chain and light-chain genes of the broadly neutralizing HIV-1-specific antibody VRC01 to humanized...
### Antiviral monoclonal antibodies in clinical development

| Antibody       | Virus                  | Antibody isolation technology | Target                      | Stage of development | Manufacturer |
|----------------|------------------------|------------------------------|-----------------------------|----------------------|--------------|
| Porgaviximab   | Ebola virus            | Immunization and chimerization| Viral Env glycoprotein      | Phase I and II       | Mapp Biopharmaceutical; LeafBio |
| MBL HCV1       | HCV                    | Humanized mice               | HCV E2 glycoprotein         | Phase II             | MassBiologics |
| PRO 140        | HIV                    | Immunization and humanization| CCR5                        | Phase III            | Progenics Pharmaceuticals |
| Ibalizumab     | HIV                    | Immunization and humanization| CD4                         | Phase III            | TaiMed Biologics |
| UB 421         | HIV                    | Immunization and humanization| CD4                         | Phase II             | United Biomedical |
| VRC01-L5       | HIV                    | Human B cell isolation       | HIV gp120                   | Phase I              | National Institute of Allergy and Infectious Diseases |
| VRC01          | HIV                    | Human B cell isolation       | HIV gp120                   | Phase I              | National Institute of Allergy and Infectious Diseases |
| 3BNC117-L5     | HIV                    | Human B cell isolation       | HIV gp120                   | Phase I              | Rockefeller University |
| 10-1074 and 3BNC117 | HIV              | Human B cell isolation       | HIV gp120                   | Phase I              | Rockefeller University |
| PGT121         | HIV                    | Human B cell isolation       | HIV gp120                   | Phase I              | International AIDS Vaccine Initiative |
| PGDM1400 and PGT121 | HIV          | Human B cell isolation       | HIV gp120                   | Phase I              | International AIDS Vaccine Initiative |
| MB 66          | HIV and HSV            | Human B cell isolation       | HIV gp120 and HSV glycoprotein D | Phase I             | Mapp Biopharmaceutical |
| VIS 410        | Influenza virus        | Unknown                      | Influenza virus HA          | Phase II             | Visterra |
| MHAA 4549A     | Influenza virus        | Human B cell isolation       | Influenza virus HA          | Phase II             | Genentech |
| CT P27         | Influenza virus        | Human B cell isolation       | Influenza virus HA          | Phase II             | Celltrion |
| Diridavumab    | Influenza virus        | Phage display                | Influenza virus HA          | Phase II             | National Institute of Allergy and Infectious Diseases |
| CR8020         | Influenza virus        | Human B cell isolation       | Influenza virus HA          | Phase II             | Crucell |
| RG 6024        | Influenza virus        | Human B cell isolation       | Influenza virus HA          | Phase I              | Genentech |
| MEDI 8852      | Influenza virus        | Human B cell isolation       | Influenza virus HA          | Phase II             | MedImmune |
| TCN 032        | Influenza virus        | Human B cell isolation       | Influenza virus M2e protein | Phase II             | Theraclove Sciences; Zenyaku Kogyo |
| m 102.4        | Nipah and Hendra virus| Phage display                | Viral Env glycoprotein G    | Phase I              | Profectus Biosciences, Inc. |
| Rabimabs       | Rabies virus           | Immunization                 | Viral Env G protein         | Phase I and II       | World Health Organization; Zydus Cadila |
| RAB-1          | Rabies virus           | Humanized mice               | Viral Env G protein         | Approved             | Serum Institute of India; MassBiologics |
| Foravirumab    | Rabies virus           | Phage display, human B cell isolation | Viral Env G protein | Phase II and III | Crucell; Sanofi Pasteur |
| Palivizumab    | RSV                    | Immunization and humanization| Viral fusion protein        | Approved             | MedImmune |
| MEDI 8897      | RSV                    | Human B cell isolation       | Viral fusion protein        | Phase II             | MedImmune |

CCRS, C-C chemokine receptor 5; E2, envelope glycoprotein (HCV); Env, envelope; gp120, envelope glycoprotein gp120; HA, haemagglutinin; HCV, hepatitis C virus; HSV, herpes simplex virus; M2e, matrix protein 2 (influenza virus); RSV, respiratory syncytial virus.
mice resulted in high serum antibody concentrations and protection against intravenous HIV-1 challenge.\(^{114}\)

Similar proof-of-concept studies have also been performed using synthetic DNA plasmid-mediated antibody gene transfer.\(^{112,113}\) In one such study, synthetic DNA plasmids encoding cross-neutralizing anti-dengue virus antibodies were delivered to mice by electroporation and resulted in biologically relevant levels of serum antibody.\(^{112}\) Importantly, a single intramuscular injection of plasmid DNA conferred protection against severe dengue disease in a mouse model. Although several technical challenges remain to be addressed, such as enhancing in vivo antibody expression levels and reducing the potential for immunogenicity, these studies demonstrate the feasibility of utilizing plasmid DNA and modified mRNA-based antibody delivery technologies for passive immunotherapy.

**Therapy.** Conventional wisdom says that antibodies are effective if present before or shortly after viral exposure, but their effectiveness declines markedly once infection is established. For example, the anti-RSV antibody palivizumab is effective in the clinic prophylactically but not therapeutically.\(^{116}\) However, there are indications that the dogma may be challenged by super-antibodies. An example is the ability of a new generation of bnAbs against HIV to strongly impact ongoing infection in animal models\(^{97,119,120}\) in which an earlier generation of less-potent mAbs had very limited effects.\(^{121}\) This ability likely reflects the increased neutralization potency of the super-antibodies as well as the increased breadth of neutralization that may restrict virus escape pathways.\(^{119}\) A number of super-antibodies are now being evaluated in humans for their activities against established HIV infection (TABLE 2). Initial results are interesting, providing for example an indication of enhanced immune responses following bnAb administration.\(^{127}\) The emerging results will be followed closely, including in the context of combining bnAbs with drugs and other antiviral agents to attempt HIV cure.

For other viruses, clear evidence of a strong therapeutic effect for super-antibodies has not been gathered yet. Several cases such as antibody treatment of rabies virus and Junin virus infections\(^{41,128}\) are probably better interpreted as prophylaxis after exposure rather than therapy for an established infection. Two promising examples of possible therapy are the successful treatment of Ebola-virus-infected or Lassa-virus-infected monkeys with mAbs once symptoms have appeared.\(^{99,129}\) Unfortunately, no definitive evidence of the effectiveness of mAbs in Ebola-symptomatic or Lassa-symptomatic humans yet exists.

Camelid-derived single-domain antibodies (sdAbs), which contain a single heavy-chain variable domain, represent a promising new class of antibody-based therapeutics for RSV and other viruses that cause lower respiratory tract infections.\(^{130-137}\) Because of their small size and high solubility and stability, sdAbs can be rapidly delivered to the site of infection via inhalation. Notably, a neutralizing anti-RSV sdAb (ALX-0171) that targets an epitope overlapping that bound by palivizumab recently showed a trend towards a therapeutic effect in a phase I and IIa clinical trial based on reduced viral loads and clinical symptoms in hospitalized RSV-infected infants. Prefusion F-protein-specific sdAbs that show up to 180,000 times greater neutralization potency than ALX-0171 have recently been identified and may offer even greater therapeutic benefit.\(^{133}\)

**Practical considerations**

Intuitively, the enhanced potency of super-antibodies is immediately recognized as beneficial in antibody prophylaxis and therapy. However, there are also a number of additional effects from this enhanced potency that may not be instantly appreciated and that can be further strengthened by antibody engineering. For example, enhanced potency means that less antibody needs to be used, and this can enable easier-to-develop, low-concentration subcutaneous administration rather than the use of more-difficult-to-develop, high-concentration subcutaneously administered formulations or less-convenient (low-concentration) intravenous administration. Enhanced potency also means that the lifetime of an effective antibody following administration is extended, thereby requiring fewer administrations to maintain a useful protective or therapeutic effect. Antibody engineering can also extend its half-life considerably\(^{95,134-137}\) so that for the most potent super-antibodies, one could envisage requiring administrations perhaps only every 3–6 months for effectiveness. Antibody engineering can also deliver greater effectiveness through enhanced Fc effector function.\(^{140,141}\)

**Conclusions**

The deployment of antibodies as antiviral agents has progressed through a number of stages over the years, corresponding to increasing levels of potency of the reagent administered. Passive immunotherapy began with immune serum over a century ago, then progressed to polyclonal antibodies, then mAbs and now into highly potent human mAbs dubbed super-antibodies. Thanks to research that has been primarily carried out in the field of cancer research, technologies have been developed to endow these super-antibodies with enhanced in vivo function.

Will super-antibodies change the landscape of antiviral prophylaxis and therapy? The answer to this question will depend on a number of factors: first, the rapidity of development of antiviral vaccines (vaccines will likely remain the least expensive and most effective antiviral measure, but some viruses such as HIV present a large challenge to vaccine development); second, the effective cost of antibody treatment, which incorporates not only manufacturing cost but also the durability of the administered antibody and the route of administration; and third, the success of antibodies in the treatment of established viral infections. Particularly in the therapeutic setting, the answers can only be obtained with clinical trials using the best super-antibodies available.
Chen, Z. Berry, J. D. & Gaudet, R. G. Antibodies in infectious diseases. J. Virol. 85, 10501–10513 (2011).

Burton, D. R. & Mascola, J. R. Antibody responses to env and gp160 in HIV infection. Nat. Immunol. 16, 571–576 (2015).

Kwong, P. D., Mascola, J. R. & Nabel, G. J. Broadly neutralizing antibodies in the search for an HIV vaccine: the end of the beginning. Nat. Rev. Immunol. 13, 693–701 (2013).

Nature 509, 59–62 (2014).

Burton, D. R. &ingerprint, L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34, 635–659 (2016).

West, A. J. et al. Structural insights on the role of antibodies in vaccine and therapy. Cell 156, 633–648 (2014).

Corti, D. & Lan炭zavecchia, A. Broadly neutralizing antibodies. Annu. Rev. Immunol. 31, 705–742 (2013).

This article is a comprehensive review of bAbs against multiple pathogens. Li, Y. et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 210, 1495–1513 (2013).

Li, G. M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109, 9047–9052 (2012).

Joyce, M. G. et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166, 609–620 (2016).

Andrews, S. F. et al. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after infection in humans. Sci. Immunol. 2, eaan2676 (2017).

Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 535, 137–141 (2016).

Burton, D. R. Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new perspectives to counter high-antigenically diverse viruses. Science 357, 185–186 (2017).

Burton, D. R. A vaccine for HIV type 1: the antibody perspective. Proc. Natl Acad. Sci. USA 94, 10018–10023 (1997).

Li, Y. et al. Broad HIV-1 neutralization mediated by CD4-specific antibodies. Nature Med. 13, 1032–1034 (2007).

Medina-Ramirez, M. et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J. Virol. 85, 426–433 (2011).

Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009).

This article presents the isolation of the first of a new generation of HIV bAbs and one of the first super-antibodies. Falkowska, E. et al. PV004, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes of CD4. J. Virol. 86, 4396–4405 (2012).

Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011).

Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimmer apex. Proc. Natl Acad. Sci. USA 111, 17624–17629 (2014).

Falkowska, E. et al. Broadly neutralizing HIV-1 antibodies define a glycan-dependent epitope on the prefusion conformation of gp120 on cleaved trimers. Immunity 40, 657–668 (2014).

Corti, D. et al. A broadly neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 335, 850–856 (2012).

This article describes the reliable generation of broadly neutralizing HIV antibodies by simple immunization in cows, suggesting that this animal has special value in super-antibody generation.
This article describes a promising approach to super-antibody generation. Priyamvada, L. et al. Cell. 26, 5480–5494 (1979).

Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature Immunol. 8, 98 (2007).

This article provides a description of a plasmablast approach to super-antibody generation. Priyamvada, L. et al. Cell. 26, 5480–5494 (1979).

and therapeutic efficacy against Venezuelan equine encephalitis virus infection. J. Immunol. Methods. 461, 43–69 (2015).

Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181–195 (2011).

J. Immunol. Methods. 481, 326ra21 (2016).

J. Immunol. Methods. 481, 326ra21 (2016).

Antibody 10–1074 suppresses viremia in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nat. Med. 21, 1692–1701 (2015).

Proc. Natl Acad. Sci. USA 110, 185–191 (2017).

Proc. Natl Acad. Sci. USA 110, 185–191 (2017).

Antibody 10–1074 suppresses viremia in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nat. Med. 21, 1692–1701 (2015).

Antibody 10–1074 suppresses viremia in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nat. Med. 21, 1692–1701 (2015).

Antibody 10–1074 suppresses viremia in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nat. Med. 21, 1692–1701 (2015).
This is a review of strategies for enhancing antibody effector function.

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642–645 (2014).

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105–109 (2016).

Engineered antibody Fc variants with extended-half-life, anti-pharmacokinetics of MEDI4893, an investigational, in vivo activity. Proc. Natl Acad. Sci. USA 103, 6005–6010 (2006).

Presta, L. C. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20, 460–470 (2008).

This is a review of strategies for enhancing antibody effector function.

Bowers, P. M. et al. Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc. Natl Acad. Sci. USA 108, 20455–20460 (2011).

Boder, E. T. & Wittrup, K. D. Yeast surface display for antibody discovery. Nat. Biotechnol. 20, 157–159 (2010).

Yu, X. Q. et al. Safety, tolerability, and pharmacokinetics of MEDI4995, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob. Agents Chemother. 61, e01020-16 (2017).

Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642–645 (2014).

Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105–109 (2016).

Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103, 6005–6010 (2006).

Presta, L. C. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20, 460–470 (2008).

This is a review of strategies for enhancing antibody effector function.

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642–645 (2014).

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105–109 (2016).

Engineered antibody Fc variants with extended-half-life, anti-pharmacokinetics of MEDI4893, an investigational, in vivo activity. Proc. Natl Acad. Sci. USA 103, 6005–6010 (2006).

Presta, L. C. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20, 460–470 (2008).

This is a review of strategies for enhancing antibody effector function.